Literatur: Fondaparinux

Als Hinweis auf potentielle weitere Informationsquellen. Kein Anspruch auf Vollständigkeit.

 

Fondaparinux

  • 1. Anderson JL, Adams CD, Antman EM, et al, »2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines," Circulation, 2011, 123(18):e426-579. [PubMed 21444888]
  • 2. Antman EM, Anbe DT, Armstrong PW, et al, »ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction),« Circulation, 2004, 110(9):e82-292. [PubMed 15339869]
  • 3. Antman EM, Hand M, Armstrong PW, et al, »2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,« J Am Coll Cardiol, 2008, 51 (2):210-49. [PubMed 18191746]
  • 4. Bauer KA, Eriksson BI, Lassen MR, et al, »Fondaparinux Compared With Enoxaparin for the Prevention of Venous Thromboembolism After Elective Major Knee Surgery,« N Engl J Med, 2001, 345:1305- 10. [PubMed 11794149]
  • 5. Bauer KA, »Fondaparinux Sodium: A Selective Inhibitor of Factor Xa,« Am J Health Syst Pharm, 2001, 58(Suppl 2):14-7. [PubMed 11715834]
  • 6. Blackmer AB, Oertel MD, and Valgus JM, »Fondaparinux and the Management of Heparin-induced Thrombocytopenia: The Journey Continues,« Ann Pharmacother, 2009, 43(!0):1636-46. [PubMed 19737996]
  • 7. Buller HR, Davidson BL, Decousus H, et al, »Fondaparinux or Enoxaparin for the Initial Treatment of Symptomatic Deep Venous Thrombosis: A Randomized Trial,« Ann Intern Med, 2004, 140 (11):867-73. [PubMed 15172900]
  • 8. Buller HR, Davidson BL, Decousus H, et al, »Subcutaneous Fondaparinux Versus Intravenous Unfractionated Heparin in the Initial Treatment of Pulmonary Embolism,« N Engl J Med, 2003, 349 (18):1695-702. [PubMed 14585937]
  • 9. Decousus H, Prandoni P, Mismetti P, et al, »Fondaparinux for the Treatment of Superficial- Vein Thrombosis in the Legs,« N Engl J Med, 2010, 363(13):1222-32. [PubMed 20860504]
  • 10. Dempfle CE, »Minor Transplacental Passage of Fondaparinux in vivo,« N Engl J Med, 2004, 350(18):1914-5. [PubMed 15115845]
  • 11. Eriksson BI, Bauer KA, Lassen MR, et al, »Fondaparinux Compared With Enoxaparin for the Prevention of Venous Thromboembolism After Hip-Fracture Surgery,« N Engl J Med, 2001, 345:1298-304. [PubMed 11794148]
  • 12. Garcia DA, Baglin TP, Weitz JI, et al, »Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,« Chest, 2012, 141(2 Suppl):24-43. [PubMed 22315264]
  • 13. Guyatt GH, Akl EA, Crowther M, et al, »Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,« Chest, 2012, 141(2 Suppl):7-47. [PubMed 22315257]
  • 14. Harenberg J, Jorg I, and Fenyvesi T, »Treatment of Heparin-induced Thrombocytopenia With Fondaparinux,« Haematologica, 2004, 89(8):1017-8. [PubMed 15339691]
  • 15. Levine GN, Bates ER, Blankenship JC, et al, »2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,« Circulation, 2011, 124(23):e574-651. [PubMed 22064601]
  • 16. Nutescu EA and Dager W, »Heparin, Low Molecular Weight Heparin, and Fondaparinux,« Managing Anticoagulation Patients in the Hospital, Gulseth M ed, American Society of Health-System Pharmacists®, Bethesda, MD: 2007, 181.
  • 17. Parody R, Oliver A, Souto JC, et al, »Fondaparinux (Arixtra®), as an Alternative Antithrombotic Prophylaxis When There is Hypersensitivity to Low Molecular Weight and Unfractionated Heparins,« Haematologica, 2007, 88(11):ECR32. [PubMed 14607764]
  • 18. Warkentin TE, Davidson BL, Buller HR, et al, »Prevalence and Risk of Preexisting Heparin- Induced Thrombocytopenia Antibodies in Patients With Acute VTE,« Chest, 2011, 140(2):366-73. [PubMed 21393394]
  • 19. Warkentin TE, Maurer BT, and Aster RH, »Heparin-Induced Thrombocytopenia Associated With Fondaparinux,« N Engl J Med, 2007, 356(25):2653-55. [PubMed 17582083]
  • 20. Yusuf S, Mehta SR, Chrolavicius S, et al, »Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes − The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators,« N Engl J Med, 2006a, 354(14):1464-76. [PubMed 16537663]
  • 21. Yusuf S, Mehta SR, Chrolavicius S, et al, »Effects of Fondaparinux on Mortality and Reinfarction in Patients With Acute ST-Segment Elevation Myocardial Infarction: The OASIS-6 Randomized Trial,« JAMA, 2006b, 295(13):1519-30. [PubMed 16537725]

 

  top |

 

 
© 2018 Prof. Dr. J. Braun